Naldemedine (Symproic®): First Global Approval – new therapeutic option for sufferers of opioid-induced constipation

Naldemedine (Symproic®): First Global Approval – new therapeutic option for sufferers of opioid-induced constipation

The recent first global approval of naldemedine has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Naldemedine (Symproic®): First Global Approval – new therapeutic option for sufferers of opioid-induced constipation”

Ribociclib (Kisqali®): First Global Approval – next-gen cyclin-dependent kinase inhibitors a new standard of care for women with advanced breast cancer

Ribociclib (Kisqali®): First Global Approval – next-gen cyclin-dependent kinase inhibitors a new standard of care for women with advanced breast cancer

The recent first global approval of ribociclib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Ribociclib (Kisqali®): First Global Approval – next-gen cyclin-dependent kinase inhibitors a new standard of care for women with advanced breast cancer”

Fail Early, Fail Fast – and increase Likelihood of approval with biomarkers

Fail Early, Fail Fast – and increase Likelihood of approval with biomarkers

Our partners Amplion recently published an interesting blog post on the benefits of biomarkers in informing earlier decisions in the drug development process – “fail early, fail fast” to save time and money, and increase approval success. An interesting read, check it out! Continue reading “Fail Early, Fail Fast – and increase Likelihood of approval with biomarkers”

Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome

Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome

The recent first global approval of telotristat ethyl has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Telotristat Ethyl (Xermelo™): First Global Approval – first and only oral drug for cancer-related diarrhoea syndrome”